Month: July 2022

Five groups that represent 340B hospitals have filed briefs in two federal appeals courts backing the federal government in its fight to force drug manufacturers Eli Lilly and AstraZeneca to end restrictions on 340B drug discounts when covered entities use

SPONSORED CONTENT

For 340B covered entities, delivering quality care and providing access to services is critical for the wellbeing of the underserved

Drug manufacturers’ decisions to impose conditions on 340B pricing when covered entities use contract pharmacies “need to be addressed moving forward,” U.S. Rep. Debbie Dingell (D-Mich.) said last week during an Energy & Commerce (E&C) health subcommittee hearing last week.

For the fourth time this year, drug manufacturer Lilly has announced refunds for overcharges on 340B-purchased drugs during 2019.

The U.S. Health Resources and Services Administration (HRSA) posted the notice, dated May 27, on the Office of Pharmacy Affairs website

Drug manufacturers Novo Nordisk and Sanofi last month urged a federal appeals court to reverse a district judge’s ruling that the companies’ conditions on 340B pricing when providers use multiple contract pharmacies violate the 340B statute.

Meanwhile, the federal government

Prescription drugs sales at 340B prices were $38.8 billion in 2020, “more than three times the level of 340B sales compared to just five years prior,” new drug industry funded research shows.

Total sales would have been $93.6 billion if

SPONSORED CONTENT

The 340B drug pricing program enables covered entities to stretch scarce federal resources as far as possible, reaching more eligible

A federal appeals court ruled unanimously this morning that a South Carolina health center has the right to challenge the legality of the government’s 340B patient definition in a lower federal court. The case ultimately could have profound implications for

Bausch Health this afternoon became the 18th drug manufacturer to impose conditions on 340B pricing when covered entities use contract pharmacies. The restrictions apply to all entities; there is no exemption for federal grantees.

According to Bausch’s announcement, effective Aug.